Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report

BACKGROUND: Sorafenib is an oral multikinase inhibitor that targets Raf serine/threonine receptor tyrosine kinases and inhibits tumor cell growth and angiogenesis. Cutaneous toxicities of sorafenib are common, including cutaneous eruptions (such as truncal erythema and seborrheic-dermatitis-like cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbas, M. Nazim, Tan, Wei Son, Kichenadasse, Ganessan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454110/
https://www.ncbi.nlm.nih.gov/pubmed/34544494
http://dx.doi.org/10.1186/s13256-021-03037-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454110/
https://www.ncbi.nlm.nih.gov/pubmed/34544494
http://dx.doi.org/10.1186/s13256-021-03037-4

Ejemplares similares